Zhongqiu Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3765110/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biology and Therapy, 2016, 17, 104-113.	3.4	264
2	Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 5.	8.6	86
3	Long noncoding RNA MALAT1-regulated microRNA 506 modulates ovarian cancer growth by targeting iASPP. OncoTargets and Therapy, 2017, Volume 10, 35-46.	2.0	59
4	Long non‑coding RNA urothelial cancer associated�1 regulates radioresistance via the hexokinase�2/glycolytic pathway in cervical cancer. International Journal of Molecular Medicine, 2018, 42, 2247-2259.	4.0	52
5	Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer. Scientific Reports, 2017, 7, 6271.	3.3	50
6	Growth arrestâ€specific 5 attenuates cisplatinâ€induced apoptosis in cervical cancer by regulating STAT3 signaling via miRâ€21. Journal of Cellular Physiology, 2019, 234, 9605-9615.	4.1	47
7	Dihydromyricetin Induces Apoptosis and Reverses Drug Resistance in Ovarian Cancer Cells by p53-mediated Downregulation of Survivin. Scientific Reports, 2017, 7, 46060.	3.3	45
8	Scutellarin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF/ERK/FAK/Src Pathway Signaling. Journal of Diabetes Research, 2019, 2019, 1-17.	2.3	42
9	miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression. Biomedicine and Pharmacotherapy, 2020, 125, 109865.	5.6	37
10	The expression of ALDH1 in cervical carcinoma. Medical Science Monitor, 2011, 17, HY21-HY26.	1.1	32
11	Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy. Annals of Surgical Oncology, 2016, 23, 163-170.	1.5	31
12	SOX2 regulates radioresistance in cervical cancer via the hedgehog signaling pathway. Gynecologic Oncology, 2018, 151, 533-541.	1.4	30
13	Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death and Disease, 2020, 11, 531.	6.3	30
14	Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125. Journal of Gynecology Obstetrics and Human Reproduction, 2018, 47, 227-230.	1.3	27
15	Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway. Tumor Biology, 2016, 37, 11469-11477.	1.8	25
16	Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. Journal of Clinical Oncology, 2022, 40, 2436-2446.	1.6	24
17	Aldehyde dehydrogenase 1 (ALDH1) positivity correlates with poor prognosis in cervical cancer. Journal of International Medical Research, 2014, 42, 1038-1042.	1.0	22
18	MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer. Oncology Letters, 2019, 18, 1049-1056.	1.8	22

Zhongqiu Lin

#	Article	IF	CITATIONS
19	Cervical cancer stem cells. Cell Proliferation, 2015, 48, 611-625.	5.3	21
20	ALDH-1-positive cells exhibited a radioresistant phenotype that was enhanced with hypoxia in cervical cancer. BMC Cancer, 2020, 20, 891.	2.6	18
21	Expression and clinical significance of transcription factor 4 (TCF4) in epithelial ovarian cancer. Cancer Biomarkers, 2019, 24, 213-221.	1.7	17
22	Galectin-3 and β-catenin are associated with a poor prognosis in serous epithelial ovarian cancer. Cancer Management and Research, 2018, Volume 10, 3963-3971.	1.9	14
23	Recommendations on management of gynecological malignancies during the COVID-19 pandemic: perspectives from Chinese gynecological oncologists. Journal of Gynecologic Oncology, 2020, 31, e68.	2.2	14
24	<i>β</i> -Catenin Expression Negatively Correlates with WIF1 and Predicts Poor Clinical Outcomes in Patients with Cervical Cancer. BioMed Research International, 2016, 2016, 1-9.	1.9	13
25	N6-Methyladenosine Associated Silencing of miR-193b Promotes Cervical Cancer Aggressiveness by Targeting CCND1. Frontiers in Oncology, 2021, 11, 666597.	2.8	13
26	Low expression of KIF7 indicates poor prognosis in epithelial ovarian cancer. Cancer Biomarkers, 2019, 26, 481-489.	1.7	11
27	Prognostic value of different metastatic sites for patients with FIGO stage IVB endometrial cancer after surgery: AÂSEER database analysis. Journal of Surgical Oncology, 2020, 122, 941-948.	1.7	11
28	Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. Clinical Cancer Research, 2022, 28, 653-661.	7.0	10
29	Application of a â€~Baseball' Suture Technique in Uterine Myomectomy Following Laparoscopic Enucleation of Uterine Leiomyoma (Fibroid). Medical Science Monitor, 2018, 24, 3042-3049.	1.1	9
30	Can pelvic lymphadenectomy be omitted in patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer?. SpringerPlus, 2016, 5, 1262.	1.2	8
31	FOXO1 overexpression is correlated with poor prognosis in epithelial ovarian cancer. Cancer Biomarkers, 2020, 28, 1-8.	1.7	8
32	LGR4 overexpression is associated with clinical parameters and poor prognosis of serous ovarian cancer. Cancer Biomarkers, 2020, 28, 65-72.	1.7	8
33	Detection of circulating tumour cells in patients with epithelial ovarian cancer by a microfluidic system. International Journal of Clinical and Experimental Pathology, 2017, 10, 9599-9606.	0.5	8
34	ls Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?. Medical Science Monitor, 2016, 22, 408-414.	1.1	7
35	Development and validation of a surgical-pathologic staging and scoring system for cervical cancer. Oncotarget, 2016, 7, 21054-21063.	1.8	7
36	High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 533-539.	1.6	7

ZHONGQIU LIN

#	Article	IF	CITATIONS
37	Risk Factors for Urinary Incontinence in Chinese Women: A Cross-sectional Survey. Female Pelvic Medicine and Reconstructive Surgery, 2021, 27, 377-381.	1.1	7
38	Chloride channel-3 is required for efficient tumour cell migration and invasion in human cervical squamous cell carcinoma. Gynecologic Oncology, 2019, 153, 661-669.	1.4	6
39	ALDH1 might influence the metastatic capability of HeLa cells. Tumor Biology, 2015, 36, 7045-7051.	1.8	5
40	Severe cervical inflammation and high-grade squamous intraepithelial lesions: a cross-sectional study. Archives of Gynecology and Obstetrics, 2021, 303, 547-556.	1.7	5
41	Protective Effects of Reduced Glutathione and Ulinastatin on Xeno-transplanted Human Ovarian Tissue Against Ischemia and Reperfusion Injury. Cell Transplantation, 2021, 30, 096368972199715.	2.5	5
42	The association between XRCC1 genetic polymorphisms and the risk of endometrial carcinoma in Chinese. Gene, 2015, 554, 155-159.	2.2	4
43	Comprehensive lymphadenectomy and survival prediction in uterine serous cancer patients after surgery: A population-based analysis. European Journal of Surgical Oncology, 2020, 46, 1339-1346.	1.0	4
44	Long non‑coding RNA AK001903 regulates tumor progression in cervical cancer. Oncology Letters, 2020, 21, 77.	1.8	4
45	Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 66-72.	1.6	3
46	Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report. Frontiers in Oncology, 2021, 11, 598594.	2.8	3
47	Elevated CA-125 Level and ER-Negative as Prognostic Factors for Ovarian Metastasis in Patients with Endometrial Cancer: A Retrospective Cohort Study. Medical Science Monitor, 2020, 26, e928826.	1.1	3
48	Co-Overexpression of GRK5/ACTC1 Correlates With the Clinical Parameters and Poor Prognosis of Epithelial Ovarian Cancer. Frontiers in Molecular Biosciences, 2021, 8, 785922.	3.5	3
49	The safety and effectiveness of preserving the ascending uterine artery in a modified fertility-sparing abdominal radical trachelectomy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 193-197.	1.1	2
50	Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1519-1530.	4.2	1
51	Round ligament suspension and vaginal purseâ€string suture: Newly optimized techniques to prevent tumor spillage in laparoscopic radical trachelectomy for cervical cancer. Journal of Obstetrics and Gynaecology Research, 2022, 48, 1867-1875.	1.3	1
52	The outcomes of â€~8'suture suspension laparoscopic radical hysterectomy for early-stage cervical carcinoma Journal of Clinical Oncology, 2021, 39, e17519-e17519.	1.6	0
53	Squamous cell carcinoma antigen combined with HPV-16 infection in predicting high-grade squamous intraepithelial lesions of the cervix. Journal of Obstetrics and Gynaecology, 2021, , 1-5.	0.9	0
54	Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial Journal of Clinical Oncology, 2020, 38, 6032-6032.	1.6	0

ZHONGQIU LIN

#	Article	IF	CITATIONS
55	Long non-coding RNA AK001903 regulates tumor progression in cervical cancer. Oncology Letters, 2021, 21, 77.	1.8	0
56	Feasibility of the "cuff-sleeve" suture method for functional neocervix reconstruction in laparoscopic radical trachelectomy: A retrospective analysis. Journal of Minimally Invasive Gynecology, 2022, , .	0.6	0
57	Survival benefit of postoperative adjuvant chemotherapy for patients in poor-differentiated early-stage cervical cancer: A multicenter, cohort study Journal of Clinical Oncology, 2022, 40, e17509-e17509.	1.6	0
58	Prognostic factors of stage I endometrioid or clear cell or mucinous ovarian cancer: Analysis based on surveillance, epidemiology, and end result program, 2000-2016 Journal of Clinical Oncology, 2022, 40, e17589-e17589.	1.6	0